Undetected rifampicin-resistant tuberculosis associated with rpoB I491F and V170F mutations in Botswana: Diagnostic implications
Journal of Global Antimicrobial Resistance · 2026
DOI: 10.1016/j.jgar.2025.12.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Global Antimicrobial Resistance, 2026. Verfasst von Tuelo Mogashoa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana; South African Medical Research Council Centre for Tuberculosis Research…. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, DNA-Directed RNA Polymerases, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FIC NIH HHS, National Institutes of Health Fogarty International Center, National Institute for Health Research.
Abstract (Originalsprache)
BACKGROUND: Undetected rifampicin resistance is a threat to global tuberculosis (TB) control efforts by delaying effective treatment. In different studies, non-canonical rpoB mutations outside the rifampicin resistance-determining region have been reported at varying prevalences by country. Here, we report cases of rifampicin resistance in Botswana that were missed by the routine molecular diagnostic assays. METHODS: Individuals were tested under routine programme conditions, in accordance with national guidelines, at four designated drug-resistant TB clinics from 2017 to 2022. Initial testing at the facilities included GeneXpert MTB/RIF ultra and later phenotypic drug susceptibility testing (pDST), as well as the Hain MTBDRsl line probe assay, at the National Tuberculosis Reference Laboratory. A total of nine isolates were subsequently sequenced on the Illumina NextSeq 2000 instrument. RESULTS: At the point of care, routine molecular tests classified all nine individuals as susceptible to rifampicin. Subsequent culture and phenotypic drug susceptibility testing confirmed rifampicin resistance. Whole-genome sequencing identified non-canonical rpoB mutations outside the rifampicin resistance-determining region I49F and V170F, which are associated with low-level rifampicin resistance. Of the nine isolates sequenced, 4 (44%) harboured the rpoB V170F mutation, while 5 (56%) harboured the rpoB I491F mutation. CONCLUSIONS: These results highlight a diagnostic gap within the current algorithms and show the value of sequencing-based approaches for accurately detecting drug resistance. Incorporating sequencing into routine clinical practice could help guide the selection of TB treatment and improve treatment outcomes in patients who do not respond to first-line therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana; South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicin…
- South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
- Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
- Ministry of Health, Botswana National Tuberculosis Program, Gaborone, Botswana.
- Botswana National Tuberculosis Reference Laboratory, Gaborone, Botswana.
- University of Antwerp, Family Medicine and Population Health, Antwerp, Belgium.
Förderung
- FIC NIH HHS
- National Institutes of Health Fogarty International Center
- National Institute for Health Research
- European Commission
- European and Developing Countries Clinical Trials Partnership
- South African Medical Research Council
Zitieren
APA
Mogashoa, T., Ngom, J. T., Loubser, J., Seru, K., Molefi, T., Stephen, O., Musonda, R. M., Gaseitsiwe, S., Warren, R. M., Dippenaar, A., Streicher, E. M., & Moyo, S. (2026). Undetected rifampicin-resistant tuberculosis associated with rpoB I491F and V170F mutations in Botswana: Diagnostic implications. Journal of Global Antimicrobial Resistance. https://doi.org/10.1016/j.jgar.2025.12.005
Vancouver
Mogashoa T, Ngom JT, Loubser J, Seru K, Molefi T, Stephen O, et al. Undetected rifampicin-resistant tuberculosis associated with rpoB I491F and V170F mutations in Botswana: Diagnostic implications. Journal of Global Antimicrobial Resistance. 2026. doi:10.1016/j.jgar.2025.12.005
BibTeX
@article{Mogashoa2026,
author = {Mogashoa, Tuelo and Ngom, Justice T and Loubser, Johannes and Seru, Kedumetse and Molefi, Tuduetso and Stephen, One and Musonda, Rosemary M and Gaseitsiwe, Simani and Warren, Robin M and Dippenaar, Anzaan and Streicher, Elizabeth M and Moyo, Sikhulile},
title = {Undetected rifampicin-resistant tuberculosis associated with rpoB I491F and V170F mutations in Botswana: Diagnostic implications},
journal = {Journal of Global Antimicrobial Resistance},
year = {2026},
doi = {10.1016/j.jgar.2025.12.005}
}
EUVIMED